Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700551 | 1.00 | CALCRL (0.53) | CALCRLMAP2K2 | |
| SCHEMBL15935913 | 0.88 | CALCRL (0.44) | CALCRLMAP2K2 | |
| SCHEMBL12921079 | 0.84 | BRD4 (0.46) | CALCRLMAP2K2 | |
| SCHEMBL1921018 | 0.84 | BRD4 (0.46) | CALCRLMAP2K2 | |
| SCHEMBL13192493 | 0.83 | CALCRL (0.43) | CALCRLMAP2K2 | |
| SCHEMBL4662273 | 0.83 | CALCRL (0.43) | CALCRLMAP2K2 | |
| SCHEMBL1394328 | 0.83 | CALCRL (0.46) | CALCRLMAP2K2 | |
| SCHEMBL1274913 | 0.83 | CALCRL (0.46) | CALCRLMAP2K2 | |
| SCHEMBL378986 | 0.83 | CALCRL (0.46) | CALCRLMAP2K2 | |
| SCHEMBL379723 | 0.81 | CALCRL (0.46) | CALCRLMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227973-B2 | Pyridine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | CALCRL, P2RX3, P2RY1 | CALCRL 1/4885MAP2K2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.